Group 1 - The economic development in Jurong is marked by significant project construction and high-quality development initiatives, with a focus on creating a strong industrial base [1] - Jiangsu Kaimi Membrane Equipment Technology Co., Ltd. is investing 1.5 billion yuan in its second phase, aiming to produce 200 sets of high-end separation membrane equipment annually, generating an additional 400 million yuan in sales [2] - Jiangsu Zhida High Voltage Electric Co., Ltd. is expanding its production capacity, with a projected doubling of output following the completion of its second phase project, which is set to be operational by October [2][3] Group 2 - Tiangong Technology Co., Ltd. is enhancing its manufacturing capabilities with the installation of advanced equipment to meet the growing demand for high-end titanium materials in various industries [3] - Jiangsu Youyuan New Materials Technology Co., Ltd. is preparing for the launch of its first production line, with expected annual output reaching 30 million yuan and plans for further expansion in the coming years [4] - The overall construction momentum in Jurong is strong, with 144 major projects underway and a planned investment of 12.205 billion yuan for the year, supported by improved business environments and expedited approval processes [5]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. plans to conduct foreign exchange hedging business with a maximum amount of RMB 600 million or equivalent foreign currency to mitigate exchange rate risks [2][3]. Group 1: Overview of Foreign Exchange Hedging Business - The purpose of the foreign exchange hedging business is to manage exchange rate and interest rate risks arising from the company's import and export operations, primarily involving foreign currency settlements [3]. - The hedging activities will be based on normal production and operations, aiming to avoid speculative and arbitrage trading [3][4]. Group 2: Transaction Amount and Funding - The company intends to use no more than RMB 600 million or equivalent foreign currency from its own funds for the hedging activities, with a maximum of RMB 30 million or equivalent foreign currency allocated for transaction margins and premiums [2][4]. - The funding will come from the company's own resources and will not involve raised funds [5]. Group 3: Transaction Methods and Approval - The hedging tools may include forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, foreign exchange interest rate swaps, foreign exchange futures, and currency swaps [5]. - The board of directors approved the hedging proposal on January 15, 2026, and this matter does not require submission to the shareholders' meeting [8]. Group 4: Risk Analysis - The foreign exchange hedging business aims to effectively manage foreign currency assets and mitigate risks from exchange rate fluctuations, although it still carries certain risks such as market risk, credit risk, and liquidity risk [9][10]. - The company will not engage in speculative trading, focusing instead on risk management [11]. Group 5: Impact on the Company and Accounting Treatment - The foreign exchange hedging activities are intended to mitigate risks from exchange rate fluctuations, and related hedging instruments will be treated as trading financial assets/liabilities according to accounting standards [13].

天眼查显示，近日，莱阳市宝利生物科技有限责任公司成立，法定代表人为于明建，注册资本2000万人 民币，由新疆禾皇生物科技有限公司全资持股。 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；生物饲料研发；生物质 燃料加工；生物基材料制造；生物基材料销售；生物农药技术研发；生物基材料技术研发；发酵过程优 化技术研发；工业酶制剂研发；细胞技术研发和应用；化肥销售；复合微生物肥料研发。（除依法须经 批准的项目外，凭营业执照依法自主开展经营活动）许可项目：乳制品生产；食品销售。（依法须经批 准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 序号股东名称持股比例1新疆禾皇生物科技有限公司100% 企业名称莱阳市宝利生物科技有限责任公司法定代表人于明建注册资本2000万人民币国标行业科学研究 和技术服务业>研究和试验发展>工程和技术研究和试验发展地址山东省烟台市莱阳市穴坊镇邵家村888 号0004-101办公楼企业类型有限责任公司(自然人投资或控股的法人独资)营业期限2026-1-15至无固定期 限登记机关莱阳市市场监督管理局 来源：市场资讯 ...

Core Viewpoint - The company, Aihuilong (688575), has announced plans to engage in foreign exchange hedging activities to mitigate currency risk, with a funding limit of up to 600 million RMB or equivalent foreign currency [1] Group 1: Stock Performance - As of January 16, 2026, Aihuilong's stock closed at 15.15 RMB, down 1.5% from the previous trading day [1] - The stock opened at 15.39 RMB, reached a high of 15.53 RMB, and a low of 15.00 RMB, with a trading volume of 1.15 billion RMB and a turnover rate of 1.33% [1] Group 2: Business Announcement - Aihuilong and its subsidiaries plan to conduct foreign exchange hedging with a maximum funding limit of 600 million RMB or equivalent foreign currency [1] - The expected maximum margin and premium for the transactions will be 30 million RMB or equivalent foreign currency, funded from the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board has approved this matter in its ninth meeting, and it does not require submission to the shareholders' meeting [1] - The purpose of this business is to avoid and prevent exchange rate risks, without engaging in speculation or arbitrage [1]

1月15日，"走进平谷.共创未来"首届韩国企业平谷行专场论坛和中韩企业冰雪联谊会活动在北京市平谷 区举办。活动通过"主题推介+企业分享+冰雪联谊"的形式，向韩国企业展示了平谷区在农业科技、现 代物流、休闲时尚等领域的发展成果与合作机会，推动双方合作从制造领域向食品健康、智慧物流、休 闲文旅等多元赛道深化延伸。 大韩贸易投资振兴公社(KOTRA)、斗山、希杰、圃美多、星宇车科技、大承株式会社等近三十家韩国 企业和商协会代表，与北京市、平谷区相关部门及企业共聚一堂，共谋发展。 活动现场，圃美多、大承株式会社、星宇车科技等已落地韩企代表分享了在平谷发展的真实感受，为潜 在投资者提供了可信参考；平谷区政府向为两地合作做出突出贡献的韩资企业代表颁发了"平谷国际友 好使者"聘书；与多家韩国企业在食品加工、新材料应用等领域签署了合作意向书。 论坛现场，韩国企业家们通过观看平谷区"农业高科技、物流大流量、休闲新时尚"的产业蓝图，深入了 解国家农业科技园区科研水平、发展前景和智慧农业场景，感受规模化物流产业集群和成熟的物流产业 生态。在"首届中韩企业冰雪联谊会"现场，嘉宾在银色山海徜徉，亲身体验时尚平谷的魅力。 活动围绕平谷区 ...

Core Insights - The Ministry of Industry and Information Technology has announced the first batch of "Biomanufacturing Pilot Capability Construction Platform List," with Huaxi Biological Technology (Tianjin) Co., Ltd. being awarded the highest "five-star" rating for its leading synthetic biology pilot platform [1][5] - Huaxi Biological is one of only five companies in the country to receive this top certification, highlighting its technological strength in the fields of cosmetics, food additives, and biopharmaceuticals [1][5] - The "five-star" certification brings attention to the critical infrastructure of pilot platforms in biomanufacturing, which is essential for bridging the gap between scientific research and industrial application [1][5] Industry Challenges and Solutions - The "valley of death" in biomanufacturing represents the significant challenge of transitioning research outcomes from the laboratory to market application, with China's technology transfer rate at only about 10% compared to 75% in developed countries [2][5] - Pilot testing is identified as a crucial step in overcoming this challenge, as it scales laboratory results from milligram to kilogram and ton levels, ensuring quality control, cost accounting, and safety verification [2][3] Huaxi Biological's Pilot Platform - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, covering 40,000 square meters and equipped with 64 pilot production lines [3][4] - The platform operates as a "biological foundry" and "debugging center," enabling year-round, green, and controllable industrial manufacturing by optimizing metabolic pathways through gene editing [3][4] - The intelligent central control system allows for real-time monitoring of thousands of indicators, enhancing predictability and control over complex biological processes [3][4] Flexibility and Cost Efficiency - The platform's modular and standardized design allows for rapid reconfiguration of production lines to meet diverse bioproduct testing needs, significantly improving equipment utilization and response speed [4] - A case study of Tianjin Zhonghe Gene Technology Co., Ltd. illustrates the platform's effectiveness, as it completed process scaling tests in one month at a 90% cost reduction compared to building its own pilot line [4] National Strategy and Industry Impact - The recognition of Huaxi Biological reflects the national strategy to develop biomanufacturing as a strategic emerging industry, with plans to cultivate over 20 pilot platforms by 2027 [5][6] - The global biomanufacturing market is projected to exceed $390 billion by 2030, positioning biomanufacturing as a key area of technological and industrial competition [5][6] - Huaxi Biological's platform serves as a public infrastructure for the industry, facilitating collaboration with universities, research institutions, and biotech startups, thus breaking down barriers between technology and industry [5][6]

Core Insights - Betaini Group has made significant progress in the upstream medical beauty industry chain with the approval of a new product by its strategic investment, Yizheng (Suzhou) Biotechnology Co., Ltd, which holds 15.73% of its shares [1][4] - The approved product, an injectable poly-L-lactic acid filler, is the first of its kind globally to be approved for use in the temporal region, marking a milestone for the company and the industry in China [1][4] Group 1 - The product received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), indicating its compliance with regulatory standards [1] - The filler utilizes proprietary MEDBIOMA® poly-L-lactic acid material and EvolaONE® microsphere technology developed by the company's core team [1][4] Group 2 - Chengdu Yizhen, founded by a team of scientists led by Dr. Zhang Xiaojin, focuses on the clinical transformation of absorbable biomaterials and has previously launched other Class III medical devices [4] - The approval of this core product signifies a strategic move by Betaini to enhance its value chain in skin health through investment and collaboration in the upstream biomaterials sector [4]

Group 1 - The core viewpoint of the news is that BGI Genomics has experienced a significant decline in its stock price, dropping 5.12% on January 16, with a cumulative decline of 8.59% over three consecutive days [1] - As of the report, BGI Genomics' stock price is at 68.32 yuan per share, with a trading volume of 274 million yuan and a turnover rate of 0.95%, resulting in a total market capitalization of 28.456 billion yuan [1] - The company, established on April 13, 2016, and listed on September 9, 2022, focuses on the life sciences and biotechnology sectors, with its main business revenue composition being 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [1] Group 2 - From the perspective of major fund holdings, one fund under ICBC Credit Suisse has a significant position in BGI Genomics, specifically the Sci-Tech Medicine ETF (588860), which reduced its holdings by 10,500 shares in the third quarter, now holding 80,900 shares, accounting for 2.72% of the fund's net value [2] - The estimated floating loss for the fund today is approximately 298,400 yuan, with a total floating loss of 547,500 yuan during the three-day decline [2] - The Sci-Tech Medicine ETF (588860) was established on August 8, 2024, with a current scale of 206 million yuan, and has achieved a year-to-date return of 9.96%, ranking 1057 out of 5531 in its category [2]

Core Insights - The event highlighted the importance of industrial funds in driving industrial upgrades and nurturing new growth drivers in Chengdu [1] - The "dual lists" released during the event aim to enhance the precision of capital and project matching, focusing on high-growth and technology-driven projects [3] Group 1: Industrial Funds and Investment - Industrial funds have become a crucial tool for local governments to promote industrial upgrades and foster new growth [1] - Chengdu High-tech Zone has signed agreements to establish 174 various funds with a total scale of 3,553 billion, enabling comprehensive capital support for advantageous industries [2] - The event featured project roadshows from companies like Guangdong Hanbang Laser Technology Co., which aims to integrate deeply into Chengdu's aerospace industry through new manufacturing options [1][2] Group 2: Project Financing and Demand - The industrial financing demand list includes 100 high-quality projects, such as Haofu Technology and Hanbang Laser, which align with Chengdu's "3+3+6" industrial system [3] - The financing projects cover key sectors like integrated circuits and healthcare, as well as emerging fields like embodied intelligence and low-altitude economy [3] - The investment direction and key tracks are clearly defined in the industrial fund investment list, which supports a three-tiered capital ecosystem [3] Group 3: Mechanisms for Capital and Project Matching - The "dual lists" are supported by the "Capital Connect" online platform, facilitating digital matching between capital and projects [3] - A combination of online and offline mechanisms, including weekly meetings and roadshows, is established to break down information barriers between capital and projects [3] - The event also featured product display and networking areas, allowing companies and investors to exchange contacts and seek collaboration opportunities [3]

Core Insights - The HuRun Research Institute released the "2025 HuRun China Unicorn Graduation List" on January 15, featuring 796 companies founded after 2000 with a valuation of over $1 billion [1] Group 1: Company Overview - The list indicates that there are over 100 listed companies in both Beijing and Shanghai, with 101 and 113 companies respectively [1] - Among the top ten companies on the list, four are headquartered in Beijing and three in Shanghai [1] Group 2: Industry Analysis - The top five industries represented in the list are semiconductors, industrial equipment, biotechnology, new energy, and software services, with 104, 96, 68, 59, and 38 companies respectively, accounting for a total of 46% of the listed companies [1] - The statistics for the list were compiled as of May 2025, and several unicorn companies have successfully gone public since that date, which are not included in this list [1]